The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Proton-driven transformable nanovaccine for cancer immunotherapy
Open accessAbstract
Cancer vaccines hold great promise for improved cancer treatment. However, endosomal trapping and low immunogenicity of tumour antigens usually limit the efficiency of vaccination strategies. Here, we present a proton-driven nanotransformer-based vaccine, comprising a polymer–peptide conjugate-based nanotransformer and loaded antigenic peptide. The nanotransformer-based vaccine induces a strong immune response without substantial systemic toxicity. In the acidic endosomal environment, the nanotransformer-based vaccine undergoes a dramatic morphological change from nanospheres (about 100 nanometres in diameter) into nanosheets (several micrometres in length or width), which mechanically disrupts the endosomal membrane and directly delivers the antigenic peptide into the cytoplasm. The re-assembled nanosheets also boost tumour immunity via activation of specific inflammation pathways. The nanotransformer-based vaccine effectively inhibits tumour growth in the B16F10-OVA and human papilloma virus-E6/E7 tumour models in mice. Moreover, combining the nanotransformer-based vaccine with anti-PD-L1 antibodies results in over 83 days of survival and in about half of the mice produces complete tumour regression in the B16F10 model. This proton-driven transformable nanovaccine offers a robust and safe strategy for cancer immunotherapy. A shape-changing pH-responsive cancer vaccine delivers antigenic peptides directly to the cytoplasm and boosts the cellular immune response upon activation of the inflammasome pathway, efficiently inhibiting tumour growth and extending survival in animal tumour models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Chiefari, J., Chong, Y. K. (., Ercole, F., Krstina, J., Jeffery, J., Le, T. P. T., Mayadunne, R. T. A., Meijs, G. F., Moad, C. L., Moad, G., et al. (1998) · Macromolecules · doi:10.1021/ma9804951 · Cited by 5,147
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Self-citationTumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Peng, S., Xiao, F., Chen, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202103836 · Cited by 441
Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments
Kolarikova, M., Hosikova, B., Dilenko, H., Barton‐Tomankova, K., Valkova, L., Bajgar, R., Malina, L., & Kolarova, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21935 · Cited by 282
pH-Responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy
Guo, S., Li, C., Wang, C., Cao, X., Liu, X., Liang, X.-J., Huang, Y., & Weng, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.001 · Cited by 36
Self-citationDesign and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines
Song, K., & Pun, S. H. (2024) · BME Frontiers · doi:10.34133/bmef.0038 · Cited by 20
Metadata
- Authors
- Gong, N., Zhang, Y., Teng, X., Wang, Y., Huo, S., Qing, G., Ni, Q., Li, X., Wang, J., Ye, X., Zhang, T., Chen, S., Wang, Y., Yu, J., Wang, P. C., Gan, Y., Zhang, J., Mitchell, M. J., Li, J., & Liang, X.-J.
- Venue
- Nature Nanotechnology
- Published
- 2020-10-26
- Volume
- 15
- Issue
- 12
- Pages
- 1053-1064
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W3094151083
- Cited by
- 300
- References
- 54
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proton-driven transformable nanovaccine for cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41565-020-00782-3
- The paper
- Gong, N., Zhang, Y., Teng, X., Wang, Y., Huo, S., Qing, G., Ni, Q., Li, X., Wang, J., Ye, X., Zhang, T., Chen, S., Wang, Y., Yu, J., Wang, P. C., Gan, Y., Zhang, J., Mitchell, M. J., Li, J., & Liang, X.-J. (2020). Proton-driven transformable nanovaccine for cancer immunotherapy. Nature Nanotechnology. https://doi.org/10.1038/s41565-020-00782-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.